BELLI, Carmen
BELLI, Carmen
Dipartimento di Farmacia e Scienze della Salute e della Nutrizione
(Ir)relevance of metformin treatment in patients with metastatic pancreatic cancer: An open-label, randomized phase II trial
2016-01-01 Reni, M.; Dugnani, E.; Cereda, S.; Belli, C.; Balzano, G.; Nicoletti, R.; Liberati, D.; Pasquale, V.; Scavini, M.; Maggiora, P.; Sordi, V.; Lampasona, V.; Ceraulo, D.; Di Terlizzi, G.; Doglioni, C.; Falconi, M.; Piemonti, L.
A demand-offer critical analysis of current drug development. Phase I drugs versus TCGA sequencing data
2023-01-01 Repetto, Matteo; Crimini, Edoardo; Belli, Carmen; Boscolo Bielo, Luca; Ascione, Liliana; Meric-Bernstam, Funda; Drilon, Alexander; Curigliano, Giuseppe
A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: Cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen)
2012-01-01 Reni, M.; Cereda, S.; Rognone, A.; Belli, C.; Ghidini, M.; Longoni, S.; Fugazza, C.; Rezzonico, S.; Passoni, P.; Slim, N.; Balzano, G.; Nicoletti, R.; Cappio, S.; Doglioni, C.; Villa, E.
Adjuvant treatment in biliary tract cancer: To treat or not to treat?
2012-01-01 Cereda, S.; Belli, C.; Reni, M.
Antiangiogenic strategies in breast cancer management
2010-01-01 Giovannini, M.; Aldrighetti, D.; Zucchinelli, P.; Belli, C.; Villa, E.
Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agents
2020-01-01 Tarantino, P.; Marra, A.; Gandini, S.; Minotti, M.; Pricolo, P.; Signorelli, G.; Criscitiello, C.; Locatelli, M.; Belli, C.; Bellomi, M.; Curigliano, G.
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents
2024-01-01 Nicolò, Eleonora; Tarantino, Paolo; D’Ecclesiis, Oriana; Antonarelli, Gabriele; Boscolo Bielo, Luca; Marra, Antonio; Gandini, Sara; Crimini, Edoardo; Giugliano, Federica; Zagami, Paola; Corti, Chiara; Trapani, Dario; Morganti, Stefania; Criscitiello, Carmen; Locatelli, Marzia; Belli, Carmen; Esposito, Angela; Minchella, Ida; Cristofanilli, Massimo; Tolaney, Sara M; Curigliano, Giuseppe
Beyond PD(L)-1 Blockade in Microsatellite-Instable Cancers: Current Landscape of Immune Co-Inhibitory Receptor Targeting
2024-01-01 Crimini, Edoardo; Boscolo Bielo, Luca; Berton Giachetti, Pier Paolo Maria; Pellizzari, Gloria; Antonarelli, Gabriele; Taurelli Salimbeni, Beatrice; Repetto, Matteo; Belli, Carmen; Curigliano, Giuseppe
Breast metastases from oligodendroglioma: An unusual extraneural spread in two young women and a review of the literature
2013-01-01 Mazza, E.; Belli, C.; Terreni, M.; Doglioni, C.; Losio, C.; Cantore, M.; Mambrini, A.; Reni, M.
Capecitabine with/without mitomycin C: Results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma
2016-01-01 Cereda, S.; Milella, M.; Cordio, S.; Leone, F.; Aprile, G.; Galiano, A.; Mosconi, S.; Vasile, E.; Santini, D.; Belli, C.; Auriemma, A.; Novarino, A.; Vaccaro, V.; Martines, C.; Marino, D.; Lutrino, S. E.; Palazzo, V.; Reinach, B.; Aldrighetti, L.; Reni, M.
Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer
2018-01-01 Duso, B. A.; Trapani, D.; Viale, G.; Criscitiello, C.; D'Amico, P.; Belli, C.; Mazzarella, L.; Locatelli, M.; Minchella, I.; Curigliano, G.
Clinical significance of skin toxicity due to EGFR-targeted Therapies
2009-01-01 Giovannini, M.; Gregorc, V.; Belli, C.; Roca, E.; Lazzari, C.; Vigano, M. G.; Serafico, A.; Villa, E.
Development and Validation of a Serum Metabolomic Signature for Endometrial Cancer Screening in Postmenopausal Women
2020-01-01 Troisi, J.; Raffone, A.; Travaglino, A.; Belli, G.; Belli, C.; Anand, S.; Giugliano, L.; Cavallo, P.; Scala, G.; Symes, S.; Richards, S.; Adair, D.; Fasano, A.; Bottigliero, V.; Guida, M.
Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden
2020-01-01 Pietrantonio, F.; Loupakis, F.; Randon, G.; Raimondi, A.; Salati, M.; Trapani, D.; Pagani, F.; Depetris, I.; Maddalena, G.; Morano, F.; Corallo, S.; Prisciandaro, M.; Corti, F.; Guarini, V.; Bocconi, A.; Marra, A.; Belli, C.; Spallanzani, A.; Fassan, M.; Lonardi, S.; Curigliano, G.; Fuca, G.; Di Bartolomeo, M.; de Braud, F.
ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research
2021-01-01 Belli, C.; Penault-Llorca, F.; Ladanyi, M.; Normanno, N.; Scoazec, J. -Y.; Lacroix, L.; Reis-Filho, J. S.; Subbiah, V.; Gainor, J. F.; Endris, V.; Repetto, M.; Drilon, A.; Scarpa, A.; Andre, F.; Douillard, J. -Y.; Curigliano, G.
Estrogen receptor (ER) and epidermal growth factor receptor (EGFR) as targets for dual lung cancer therapy: Not just a case?
2008-01-01 Giovannini, M.; Belli, C.; Villa, E.; Gregorc, V.
Evaluation of the Geographical Accessibility of Genome-Matched Clinical Trials on a National Experience
2024-01-01 Crimini, Edoardo; Tini, Giulia; Tarantino, Paolo; Ascione, Liliana; Repetto, Matteo; Beria, Paolo; Ranghiero, Alberto; Marra, Antonio; Belli, Carmen; Criscitiello, Carmen; Esposito, Angela; Guerini Rocco, Elena; Barberis, Massimo C P; Mazzarella, Luca; Curigliano, Giuseppe
Evidence for interleukin 17 involvement in severe immune-related neuroendocrine toxicity
2020-01-01 Mazzarella, L.; Giugliano, S.; D'Amico, P.; Belli, C.; Duso, B. A.; Rescigno, M.; Curigliano, G.
Expression of the oncoproteins p16, p53 and Ki67 as predictive value in the differentiation of low-grade intracervical neoplasms of high and low risk
2021-01-01 Goglia, P.; Dalena, A. M.; De Vanna, A. C.; Sorrentino, A.; Belli, C.; Belli, M.
Homologous recombination deficiency in triple negative breast cancer
2019-01-01 Belli, C.; Duso, B. A.; Ferraro, E.; Curigliano, G.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| (Ir)relevance of metformin treatment in patients with metastatic pancreatic cancer: An open-label, randomized phase II trial | 1-gen-2016 | Reni, M.; Dugnani, E.; Cereda, S.; Belli, C.; Balzano, G.; Nicoletti, R.; Liberati, D.; Pasquale, V.; Scavini, M.; Maggiora, P.; Sordi, V.; Lampasona, V.; Ceraulo, D.; Di Terlizzi, G.; Doglioni, C.; Falconi, M.; Piemonti, L. | |
| A demand-offer critical analysis of current drug development. Phase I drugs versus TCGA sequencing data | 1-gen-2023 | Repetto, Matteo; Crimini, Edoardo; Belli, Carmen; Boscolo Bielo, Luca; Ascione, Liliana; Meric-Bernstam, Funda; Drilon, Alexander; Curigliano, Giuseppe | |
| A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: Cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen) | 1-gen-2012 | Reni, M.; Cereda, S.; Rognone, A.; Belli, C.; Ghidini, M.; Longoni, S.; Fugazza, C.; Rezzonico, S.; Passoni, P.; Slim, N.; Balzano, G.; Nicoletti, R.; Cappio, S.; Doglioni, C.; Villa, E. | |
| Adjuvant treatment in biliary tract cancer: To treat or not to treat? | 1-gen-2012 | Cereda, S.; Belli, C.; Reni, M. | |
| Antiangiogenic strategies in breast cancer management | 1-gen-2010 | Giovannini, M.; Aldrighetti, D.; Zucchinelli, P.; Belli, C.; Villa, E. | |
| Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agents | 1-gen-2020 | Tarantino, P.; Marra, A.; Gandini, S.; Minotti, M.; Pricolo, P.; Signorelli, G.; Criscitiello, C.; Locatelli, M.; Belli, C.; Bellomi, M.; Curigliano, G. | |
| Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents | 1-gen-2024 | Nicolò, Eleonora; Tarantino, Paolo; D’Ecclesiis, Oriana; Antonarelli, Gabriele; Boscolo Bielo, Luca; Marra, Antonio; Gandini, Sara; Crimini, Edoardo; Giugliano, Federica; Zagami, Paola; Corti, Chiara; Trapani, Dario; Morganti, Stefania; Criscitiello, Carmen; Locatelli, Marzia; Belli, Carmen; Esposito, Angela; Minchella, Ida; Cristofanilli, Massimo; Tolaney, Sara M; Curigliano, Giuseppe | |
| Beyond PD(L)-1 Blockade in Microsatellite-Instable Cancers: Current Landscape of Immune Co-Inhibitory Receptor Targeting | 1-gen-2024 | Crimini, Edoardo; Boscolo Bielo, Luca; Berton Giachetti, Pier Paolo Maria; Pellizzari, Gloria; Antonarelli, Gabriele; Taurelli Salimbeni, Beatrice; Repetto, Matteo; Belli, Carmen; Curigliano, Giuseppe | |
| Breast metastases from oligodendroglioma: An unusual extraneural spread in two young women and a review of the literature | 1-gen-2013 | Mazza, E.; Belli, C.; Terreni, M.; Doglioni, C.; Losio, C.; Cantore, M.; Mambrini, A.; Reni, M. | |
| Capecitabine with/without mitomycin C: Results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma | 1-gen-2016 | Cereda, S.; Milella, M.; Cordio, S.; Leone, F.; Aprile, G.; Galiano, A.; Mosconi, S.; Vasile, E.; Santini, D.; Belli, C.; Auriemma, A.; Novarino, A.; Vaccaro, V.; Martines, C.; Marino, D.; Lutrino, S. E.; Palazzo, V.; Reinach, B.; Aldrighetti, L.; Reni, M. | |
| Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer | 1-gen-2018 | Duso, B. A.; Trapani, D.; Viale, G.; Criscitiello, C.; D'Amico, P.; Belli, C.; Mazzarella, L.; Locatelli, M.; Minchella, I.; Curigliano, G. | |
| Clinical significance of skin toxicity due to EGFR-targeted Therapies | 1-gen-2009 | Giovannini, M.; Gregorc, V.; Belli, C.; Roca, E.; Lazzari, C.; Vigano, M. G.; Serafico, A.; Villa, E. | |
| Development and Validation of a Serum Metabolomic Signature for Endometrial Cancer Screening in Postmenopausal Women | 1-gen-2020 | Troisi, J.; Raffone, A.; Travaglino, A.; Belli, G.; Belli, C.; Anand, S.; Giugliano, L.; Cavallo, P.; Scala, G.; Symes, S.; Richards, S.; Adair, D.; Fasano, A.; Bottigliero, V.; Guida, M. | |
| Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden | 1-gen-2020 | Pietrantonio, F.; Loupakis, F.; Randon, G.; Raimondi, A.; Salati, M.; Trapani, D.; Pagani, F.; Depetris, I.; Maddalena, G.; Morano, F.; Corallo, S.; Prisciandaro, M.; Corti, F.; Guarini, V.; Bocconi, A.; Marra, A.; Belli, C.; Spallanzani, A.; Fassan, M.; Lonardi, S.; Curigliano, G.; Fuca, G.; Di Bartolomeo, M.; de Braud, F. | |
| ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research | 1-gen-2021 | Belli, C.; Penault-Llorca, F.; Ladanyi, M.; Normanno, N.; Scoazec, J. -Y.; Lacroix, L.; Reis-Filho, J. S.; Subbiah, V.; Gainor, J. F.; Endris, V.; Repetto, M.; Drilon, A.; Scarpa, A.; Andre, F.; Douillard, J. -Y.; Curigliano, G. | |
| Estrogen receptor (ER) and epidermal growth factor receptor (EGFR) as targets for dual lung cancer therapy: Not just a case? | 1-gen-2008 | Giovannini, M.; Belli, C.; Villa, E.; Gregorc, V. | |
| Evaluation of the Geographical Accessibility of Genome-Matched Clinical Trials on a National Experience | 1-gen-2024 | Crimini, Edoardo; Tini, Giulia; Tarantino, Paolo; Ascione, Liliana; Repetto, Matteo; Beria, Paolo; Ranghiero, Alberto; Marra, Antonio; Belli, Carmen; Criscitiello, Carmen; Esposito, Angela; Guerini Rocco, Elena; Barberis, Massimo C P; Mazzarella, Luca; Curigliano, Giuseppe | |
| Evidence for interleukin 17 involvement in severe immune-related neuroendocrine toxicity | 1-gen-2020 | Mazzarella, L.; Giugliano, S.; D'Amico, P.; Belli, C.; Duso, B. A.; Rescigno, M.; Curigliano, G. | |
| Expression of the oncoproteins p16, p53 and Ki67 as predictive value in the differentiation of low-grade intracervical neoplasms of high and low risk | 1-gen-2021 | Goglia, P.; Dalena, A. M.; De Vanna, A. C.; Sorrentino, A.; Belli, C.; Belli, M. | |
| Homologous recombination deficiency in triple negative breast cancer | 1-gen-2019 | Belli, C.; Duso, B. A.; Ferraro, E.; Curigliano, G. |